Trial Profile
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2022
Price :
$35
*
At a glance
- Drugs Acumapimod (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms AETHER
- Sponsors Mereo BioPharma
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
- 20 Mar 2018 According to a Mereo BioPharma media release, positive data from the study will be presented at the American Thoracic Society (ATS) 2018 International Conference.
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.